Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A comparison study of the turnaround time for telepsychiatry versus face-to-face consultations in general hospital nonpsychiatric emergency rooms.

Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists·2020
Same author

Scaling the great wall: The impact of communication barriers on quality of psychiatric care in Chinese patients.

The International journal of social psychiatry·2019
Same author

The psychopharmacology of primary and metastatic brain tumors and paraneoplastic syndromes.

Handbook of clinical neurology·2019
Same author

The sound of music: A rare case of auditory Charles Bonnet syndrome in an elderly male.

Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists·2019
Same author

Persistent Psychosis due to Single Dose of Ecstasy.

Cureus·2018
Same author

Psychiatric symptoms associated with porphyria: A case report and brief review.

Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists·2017
Same journal

Explainable Artificial Intelligence in Pharmacovigilance and Drug Safety: A Systematic Review of Enhancing Transparency and Regulatory Acceptance.

Current drug safety·2026
Same journal

Intravenous Methylcobalamin-Induced Anaphylactic Shock: A Case Report.

Current drug safety·2026
Same journal

Nasal Bleeding as a Potential Side Effect of Omega-3 Fatty Acids: A Case Report.

Current drug safety·2026
Same journal

Pharmacovigilance Analysis of Azelastine-Related Adverse Events: Insights from the FDA FAERS Database (2006-2024).

Current drug safety·2026
Same journal

Assessing the Risk of Drug-Induced Influenza-Like Illness: A Disproportionality Analysis of Two Decades of FAERS Data (2004-2025).

Current drug safety·2026
Same journal

Pharmacovigilance Assessment of Thrombotic Adverse Events Linked to GLP-1 Receptor Agonists: Analysis of FAERS Reports from 2020-2025.

Current drug safety·2026
See all related articles

Related Experiment Video

Updated: Jun 13, 2026

Paw-Print Analysis of Contrast-Enhanced Recordings (PrAnCER): A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits
06:25

Paw-Print Analysis of Contrast-Enhanced Recordings (PrAnCER): A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits

Published on: August 12, 2019

Paliperidone use in the elderly.

Subramoniam Madhusoodanan1, Deval Zaveri

  • 1Department of Psychiatry, St John's Episcopal Hospital, 327 Beach 19th Street, Far Rockaway, New York 11691, USA. sdanan@ehs.org

Current Drug Safety
|April 22, 2010
PubMed
Summary
This summary is machine-generated.

Paliperidone, an effective schizophrenia treatment, shows promise for elderly patients. Limited data suggest it may be both safe and effective in this population.

Related Experiment Videos

Last Updated: Jun 13, 2026

Paw-Print Analysis of Contrast-Enhanced Recordings (PrAnCER): A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits
06:25

Paw-Print Analysis of Contrast-Enhanced Recordings (PrAnCER): A Low-Cost, Open-Access Automated Gait Analysis System for Assessing Motor Deficits

Published on: August 12, 2019

Area of Science:

  • Psychiatry
  • Geriatric Medicine
  • Pharmacology

Background:

  • Paliperidone, the active metabolite of risperidone, is a newer antipsychotic medication.
  • Schizophrenia treatment in the elderly is complex, with limited specific data for newer agents.
  • Understanding the efficacy and safety of paliperidone in geriatric populations is crucial.

Purpose of the Study:

  • To review and highlight key aspects of paliperidone use in elderly patients with schizophrenia.
  • To address the paucity of data regarding paliperidone in geriatric populations.
  • To evaluate the potential effectiveness and safety profile of paliperidone in this demographic.

Main Methods:

  • Literature review focusing on studies involving paliperidone in elderly patients.
  • Analysis of available clinical data on efficacy and safety outcomes.
  • Synthesis of findings to provide a comprehensive overview.

Main Results:

  • Limited but emerging data suggest paliperidone's potential efficacy in treating schizophrenia symptoms in the elderly.
  • Available evidence indicates a potentially favorable safety profile for paliperidone in geriatric patients.
  • Paliperidone may offer a viable treatment option for schizophrenia in older adults.

Conclusions:

  • Paliperidone demonstrates potential as an effective treatment for schizophrenia in the elderly.
  • Current limited data suggest paliperidone is safe for use in the geriatric population.
  • Further research is warranted to confirm long-term efficacy and safety in elderly patients.